Acromegaly Market Overview
The global Acromegaly Market is set to grow at a CAGR of 5.10% during the forecast period according to Market Research Future in its report on the Acromegaly Market. This hormonal disorder is diagnosed in those with a heavy secretion of growth hormones from the pituitary gland. This can result in enlarged hands, feet and an abnormally enlarged face. Limited treatment methods are available. However, acromegaly is an incurable condition that may sometimes go into remission by itself. Acromegaly is a chronic metabolic disorder caused by excess secretion of growth hormone (GH) by the pituitary gland. The excess secretion of GH results in gradual enlargement of body tissues including the bones of the face, jaw, hands, feet, and skull. Acromegaly is a rare disease.
Acromegaly is a hormonal disorder caused by the excessive amount of growth hormones which can cause abnormal bone growth and a rise in height size. It can also cause gigantism in children in the midst of puberty. Untimely treatment of the disorder can culminate in arthritis, cardiovascular disease, type 2 diabetes, and high blood pressure. The global Acromegaly Market report by Market Research Future (MRFR) outlines trends, drivers, opportunities, and threats for manufacturers offering treatments and solutions for the disorder.
If the diseases remains untreated, it may cause serious illness and premature death. The market is experiencing rapid growth owing to increasing prevalence of acromegaly, changing lifestyle and increasing need for better treatment & cost-effective treatment. Additionally, increasing government support along with the per capita income fuels the market growth. However, the cost of the treatment ranges from USD 2,800 to USD 9,200. On the other hand, the market may witness slow growth over the assessment period due to high cost of treatment and limited number of treatment.
Acromegaly Market Segmentation
The global acromegaly market is segmented on the basis of diagnosis, types, treatment, and end-users. By types, the market is segmented into acromegaly due to growth hormone, ectopic acromegaly, and others. By diagnosis, the acromegaly market is divided into medical laboratory investigations, medical imaging, and others. The medical imaging segment is sub-segmented to include MRI, radiography, nuclear medicine, ultrasound, and others.
By treatment, the market is categorized into surgery, medication, radiation therapy, and others. The medication segment is sub-segmented into dopamine agonists, somatostatin analogs, growth hormone receptor antagonists, and others. The surgery segment is sub-segmented to include transsphenoidal surgery and endonasal transsphenoidal surgery. By end-users, the market is comprised of clinics, hospitals, and others.
Acromegaly Market Regional Analysis
Geography-wise, the global acromegaly market comprises the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas is expected to be the dominating region of the acromegaly market due to the increasing prevalence of the hormonal disorder. Rising number of incidents as well as expendable income levels of patients can fuel the regional market growth. Presence of pharmaceutical majors, government support for research and development, and extended healthcare expenditure are other drivers in the region. Approval of bills which outline the procurement of unproven drugs and vaccines by patients for the treatment of orphan or rare diseases.
The Europe market is driven by increasing investments in research and development centers and rising government support. The inflated healthcare expenditure
APAC is touted to exhibit the highest growth rate during the forecast timespan due to rising prevalence of hormonal disorders, developing healthcare sector, and a large patient pool. China and India can contribute to the market revenue due to hiring of skilled personnel capable of providing treatment for the hormonal disorder as well as availability of drugs in the region.
Lastly, the MEA region can exhibit a sluggish growth rate due to low awareness levels and limited availability of suitable drugs.
Acromegaly Market Players
- Novartis AG (Switzerland)
- Aegis Therapeutics LLC (US)
- Chiasma Inc (US)
- Crinetics Pharmaceuticals Inc (US)
- Daewoong Pharmaceutical Co Ltd (South Korea)
- Peptron Inc (South Korea)
- Silence Therapeutics Plc (UK)
- Strongbridge Biopharma plc (US)
- Amryt Pharma plc (UK)
- Foresee Pharmaceuticals LLC (US)
- Others
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/acromegaly-market-4429
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
